McAndrews

About

  • The Orange Book blog team are a group of attorneys with McAndrews, Held and Malloy, which is a full-service IP firm representing both brands and generics in various aspects of IP law. This blog does not provide legal advice. If you are seeking legal advice, please contact the author directly.

Disclaimer

  • Orange Book Blog is published for informational purposes only; it contains no legal advice whatsoever. Publication of Orange Book Blog does not create an attorney-client relationship. Orange Book Blog is not edited by McAndrews, Held & Malloy, Ltd. ("MHM") or its clients. The views expressed are solely those of the authors, and may not reflect the views of MHM or its clients. No part of Orange Book Blog--whether information, commentary, or other--may be attributed to MHM or its clients. MHM represents many companies in the pharmaceutical and biotechnology industries, and therefore Orange Book Blog may occasionally report on news that relates to MHM clients. Orange Book Blog will always strive to be unbiased. All information on Orange Book Blog should be double-checked for its accuracy and current applicability.

« Federal Circuit Affirms Decision Holding Lovenox Patent Unenforceable | Main | OBB News Briefs »

May 16, 2008

IIR "Generic Drugs Summit," Washington, D.C., June 18-20

The Institute for International Research will be holding its 9th annual "Generic Drugs Summit," June 18-20 in Washington, D.C.

According to IIR, this is "the leading independent forum addressing business and legal concerns impacting the generics marketplace.  This event attracts 200+ senior-level professionals representing government, regulatory and legal affairs as well as marketing, sales and business development."

The agenda on June 19-20 includes many interesting presentations:

  • "Update on Hatch-Waxman Reform," by none other than Rep. Henry A. Waxman
  • "Removing Hurdles that Slow Affordable Generics from Coming to Market," by Sen. Debbie A. Stabenow
  • "The Future of Biogenerics and Other Measures to Reduce Healthcare Costs," by Rep. Frank Pallone, Jr.
  • "Federal Trade Commission Actions Involving Generic Drugs," by Phil Eisenstat, Sr. Attorney, FTC
  • "Patent Reform: A Generic Industry Friend or Foe?"
  • "The Changing Competitive Landscape of the Generic Drugs Industry"
  • "Understanding the 180-Day Forfeiture Provisions of the MMA" (I'll be presenting this topic)
  • "Trends in New Pharmaceutical Patent Claim Strategies"

In addition, the Generic Drugs Summit features two pre-conference workshops on June 18: "Strategies for Filing Successful Paragraph IV Certifications" and "Understanding How to Submit Quality ANDAs Based on QbR to Reduce Approval Time."

For more information or to register, please visit the conference website.

Posted by in Conferences |

Comments

Verify your Comment

Previewing your Comment

Posted by:  | 

This is only a preview. Your comment has not yet been posted.

Working...
Your comment could not be posted. Error type:
Your comment has been saved. Comments are moderated and will not appear until approved by the author. Post another comment

The letters and numbers you entered did not match the image. Please try again.

As a final step before posting your comment, enter the letters and numbers you see in the image below. This prevents automated programs from posting comments.

Having trouble reading this image? View an alternate.

Working...

Post a comment

Comments are moderated, and will not appear until the author has approved them.

Your Information

(Name is required. Email address will not be displayed with the comment.)

Subscribe

* indicates required

Search

Categories

Archives

More...